SHERONA BAU: Open Payments
NPI 1902056062 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,891 in 43 payments from 10 companies in 2025. Trend: 2023 $3,766 · 2024 $12,361 · 2025 $12,891
Speaker / faculty: $4,710Consulting: $4,600Food & beverage: $2,119Travel & lodging: $1,462
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $4,158 |
| Madrigal Pharmaceuticals | 7 | $3,526 |
| Ipsen Biopharmaceuticals, Inc | 6 | $2,734 |
| GlaxoSmithKline, LLC. | 1 | $1,350 |
| Gilead Sciences, Inc. | 9 | $591 |
| Alnylam Pharmaceuticals Inc. | 3 | $211 |
| Mirum Pharmaceuticals, Inc. | 1 | $142 |
| Novo Nordisk Inc | 1 | $125 |
| ABBVIE INC. | 1 | $34 |
| Intercept Pharmaceuticals, Inc. | 1 | $20 |
Products named: TRULANCE, REZDIFFRA, IQIRVO, GIVLAARI, Livmarli, Vemlidy, XIFAXAN, Wegovy.
Industry payments across CA — which companies pay providers there.
